Who Paid My Doc
Mark Tulchinsky
Nuclear Medicine Hershey, PA Medical Doctor
NPI 1699733022 CMS profile 468766
500 University Dr, Hershey, PA 17033
General payments
$385
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Mark Tulchinsky of Hershey, PA is reported in the CMS Open Payments database as having received $385 across 5 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 62nd percentile of Nuclear Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $215 | 2 | |
| 2024 | General | $83 | 1 | |
| 2020 | General | $63 | 1 | |
| 2019 | General | $24 | 1 |
Beside peers
- Mark Tulchinsky
- Nuclear Medicine median
- Middle half of Nuclear Medicine
- National median
In program year 2025, general payments to Mark Tulchinsky were reported at $215. Among 197 Nuclear Medicine profiles paid that year, the median was $146 and the middle half received between $40 and $372.
Show as a table
| Year | Mark Tulchinsky | Nuclear Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $24 | $125 | $54–$531 | $163 |
| 2020 | $63 | $99 | $34–$2,125 | $114 |
| 2021 | $0 | $96 | $22–$874 | $132 |
| 2022 | $0 | $102 | $38–$240 | $149 |
| 2023 | $0 | $123 | $51–$257 | $160 |
| 2024 | $83 | $121 | $51–$390 | $164 |
| 2025 | $215 | $146 | $40–$372 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 30 billing codesPaid by Medicare
$20,597
Medicare patients
552
Services billed
601
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 69% | |
| Arthritis | 51% | |
| Osteoporosis | 36% | |
| Cancer | 28% | |
| Diabetes | 27% | |
| Depression | 25% | |
| Ischemic heart disease | 23% | |
| Chronic kidney disease | 23% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
5 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Nuclear Medicine in Pennsylvania
Neeta Pandit-Taskar
Nuclear Medicine · Pittsburgh, PA
Daniel Pryma
Nuclear Medicine · Philadelphia, PA
Abass Alavi
Nuclear Medicine · Philadelphia, PA
David Mankoff
Nuclear Medicine · Philadelphia, PA
Hongming Zhuang
Nuclear Medicine · Philadelphia, PA
John Hochhold
Nuclear Medicine · Philadelphia, PA
Related records
Nuclear Medicine in Pennsylvania
Practitioners in the same specialty and state, ranked by reported value.
All Nuclear Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Pennsylvania
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.